134 articles - From Friday May 08 2026 to Friday May 15 2026
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Aliment Pharmacol Ther |
|---|
| Editorial: UDCA Dosing in PBC - Between Guideline Adherence and Clinical Reality. |
| Am J Gastroenterol |
| Guidelines in Practice: Preoperative Risk Assessment and Management in Patients with Cirrhosis. |
| Endoscopy |
| Endoscopic diagnosis and management of peptic ulcer bleeding: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2026.
Postendoscopy management 18: ESGE suggests that iron therapy be initiated prior to hospital discharge in patients with peptic ulcer bleeding and iron deficiency and/or anemia. Postendoscopy management 19: ESGE suggests that early oral nutrition, within 24 hours following endoscopic hemostasis, be initiated in patients with peptic ulcer bleeding in whom durable hemostasis has been achieved. |
| Sustainability in endoscopic medical congresses and courses: Position Statement from the European Society of Gastrointestinal Endoscopy and the European Society of Gastroenterology and Endoscopy Nurses and Associates.
Emphasis is placed on promoting virtual and hybrid conference formats, low-emission travel options, sustainable venues and catering, and the systematic measurement and transparent reporting of environmental impact. This ESGE-ESGENA Position Statement provides practical, consensus-based, evidence-informed guidance to support GI endoscopy societies, conference organizers, industry partners, and participants in reducing the environmental impact of endoscopy-related educational activities while preserving their scientific and educational quality. |
| Hepatology |
| Definition, diagnosis, and treatment of primary biliary cholangitis - autoimmune hepatitis (PBC-AIH) variant: An international expert delphi consensus.
This Delphi initiative established consensus in a complex, understudied area lacking evidence-based guidelines. The resulting statements offer a basis for prospective studies and standardized clinical protocols, aiming to enhance consistent management of PBC-AIH. |
meta-analyses and systematic reviews
| Endoscopy |
|---|
| Neoplastic recurrence after colorectal endoscopic submucosal dissection at scheduled endoscopic surveillance: A systematic review and meta-analysis.
Neoplastic recurrence is rare up to 5-year endoscopic surveillance, especially in those with R0 resection and favorable histology. In low-risk patients, an extended 3-5-year surveillance interval should be considered, mostly based on an increased risk of metachronous lesions. |
| Gastrointest Endosc |
| Risk Factors for Bleeding Following Endoscopic Retrograde Cholangiopancreatography: A Systematic Review and Meta-analysis.
In conclusion, this meta-analysis identified that the anticoagulation therapy, cirrhosis, hemodialysis, coagulation disorder, endoscopic sphincterotomy, precut sphincterotomy, and male gender are associated with an increased odds of post-ERCP bleeding in the pooled adjusted analysis. Conversely, age, high BMI, cholangitis, choledocholithiasis, pancreatic duct stones, needle-knife sphincterotomy, NSAIDs use, and antiplatelet therapy were not significantly associated with higher odds of post-ERCP bleeding in pooled adjusted analysis. Incorporating our results into a prediction model may assist in identifying patients at increased risk, optimizing informed consent, and guiding prevention and management strategies for post-ERCP bleeding. |
| Gut |
| Hepatocellular carcinoma attributable to hepatitis B, hepatitis C and other risk factors at global, regional and national levels: an updated systematic review and meta-analysis.
These data can inform viral hepatitis prevention strategies. CRD42023397708. |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
| Asian Patients Report Higher Reflux Symptom Burden than US Patients Despite Lower Objective Reflux Burden.
On multivariable linear regression, Asian patients (β = 19.3, p < 0.0001), higher AET (β = 1.02, p = 0.0004), higher reflux episodes (β = 0.11, p = 0.0029), lower BMI (β = -0.37, p = 0.0046) and female sex (β = 8.14, p = 0.0007) were independent predictors for higher GSS. Compared to US patients, GERD profiles in Asian patients associate with higher symptom reporting despite lower objective reflux burden. |
| Clinical trial: Efficacy of a Low FODMAP Diet in Paediatric Irritable Bowel Syndrome-A Randomised Crossover Trial With Exploratory Metabolomic Analysis.
In this randomised crossover trial, a LFD improved abdominal pain and symptom severity in children with IBS, with the greatest benefit in those with severe baseline pain. Exploratory faecal and urinary metabolomic analyses identified candidate features associated with non-response, warranting further validation. |
| Epidemiology, Predictors of Antimicrobial Resistance and Empiric Treatment Strategies for Spontaneous Bacterial Peritonitis in Cirrhosis: A Multicentre SBP-INDIA Study.
There is a high burden of MDRO and CRO in ascitic infections among hospitalized patients with cirrhosis, with clinically relevant impact on outcomes. Empiric antibiotic selection should be guided by acquisition setting, illness severity and resistance risk factors, with stewardship oversight. Similar outcomes between NNBA and SBP suggest that microbiological evidence, rather than neutrophil count alone, should guide decisions. |
| Genetic Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance and Its Associated Viral Markers.
Although host genetic factors may influence HBV replication through immune-mediated mechanisms, their impact on HBsAg levels is limited by its dual origin from cccDNA and integrated HBV DNA. These findings enhance understanding of host genetic contributions to HBV traits, though further research is needed to clarify their role in HBsAg seroclearance and guiding immunomodulatory therapies. |
| P-CAB vs. PPI for Upper Gastrointestinal Bleeding Prevention in Patients With Atherothrombotic Disease on Antithrombotic Therapy: A CDM Cohort Study.
In patients receiving antithrombotic therapy, P-CABs are associated with a significantly lower risk of clinically significant GI bleeding compared to PPIs. These findings support P-CABs as a potent acid-suppressive strategy for gastroprotection in high-risk populations. |
| Rifaximin Improves Cognitive Performance and Reduces Cirrhosis-Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial.
RFX improved cognitive performance assessed by the Stroop test and reduced cirrhosis-related adverse events in patients with CHE. These randomized data support RFX as an effective therapeutic option and highlight the Stroop test as a sensitive endpoint for treatment response. |
| Secular Trend in Glycaemic Management in Type 2 Diabetes Patients With and Without Cirrhosis Between 2000 and 2023: A Territory-Wide Cohort Study.
Glycaemic control improved in T2DM patients irrespective of cirrhosis status. Further research is needed to determine the impact of sustained control on hepatic and extrahepatic outcomes. |
| Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis.
In the United Kingdom, ALD exhibited the highest liver, cardiovascular, and mortality risks, while MASLD and MetALD had similar cardiovascular and survival profiles but differed in liver-related risk. |
| Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score-Matched Study Using Linear Mixed-Effects Models.
This evidence supports personalised treatment selection for functional cure. |
| Synergistic Effects of Type 2 Diabetes and Alcohol on All-Cause and Liver-Related Mortality in Steatotic Liver Disease.
Co-exposure to T2D and alcohol intake substantially increased the risk of all-cause and liver-related mortality among individuals with SLD. Their interplay conferred significant disease burden, underscoring the importance of alcohol abstinence and glycemic control in this population. |
| Am J Gastroenterol |
| Body surface colonic mapping detects meal and bisacodyl-induced colonic motility in patients with chronic constipation.
BSCM accurately detects meal and bisacodyl-induced increases in colonic motility with high fidelity to invasive HRM. BSCM could be applied in larger cohort studies to elucidate symptom-motility associations and guide personalized management in refractory chronic constipation. |
| GLP-1 receptor agonist use and liver-related outcomes in MASLD and type 2 diabetes in the All of Us Research Program.
In a nationwide, diverse cohort of individuals with MASLD and T2DM, GLP-1 RA use was associated with a reduction in hepatic complication events, supporting a potential hepatoprotective effect in real-world clinical practice. |
| Improvement in Health-Related Quality of Life in Patients With Moderate to Severe Crohn's Disease Treated With Risankizumab Versus Ustekinumab in the Phase 3B SEQUENCE Study.
RZB was more effective than UST in achieving sustained clinically meaningful PRO improvements including IBDQ response and remission, and in reducing frequency of select symptoms of the IBDQ through week 48 among patients with moderate-to-severe CD. |
| Clin Gastroenterol Hepatol |
| A TIME DEPENDENT PROGNOSTIC SCORE (HelPSCore) TO PREDICT DISEASE OUTCOMES IN PRIMARY SCLEROSING CHOLANGITIS.
HelPSCore provides a straightforward and reliable tool for short- and long-term PSC prognosis. This enables the identification of high-risk patients who may benefit from intensified monitoring and tailored therapy. |
| Esophageal Dysmotility and Gastroesophageal Reflux Disease Risk in Hypermobile Ehlers-Danlos Syndrome.
Patients with hEDS/HSD who present to tertiary units with dysphagia or reflux symptoms and undergo HRM or 24-hour pH-impedance monitoring, respectively, are not at increased risk of Chicago v4.0 esophageal dysmotility or Lyon v2.0 GERD compared with non-hypermobile patient controls. |
| Fibrosis progression rate and comparison of paired liver biopsy versus non-invasive tests as surrogate endpoints for clinical trials in MetALD and ALD.
Active alcohol consumption determines fibrosis progression in ALD and MetALD. Non-invasive biomarkers are promising surrogate markers for understanding disease dynamics and monitoring in ALD and MetALD clinical trials. |
| Frailty increases hospitalization rates in an ambulatory cohort of patients with cirrhosis: The NACSELD3 prospective cohort.
Measures of frailty (by LFI) and functional capacity (by DASI) independently predict 6-month hospitalization in ambulatory cirrhosis patients. One third of frail patients and almost one quarter of pre-frail patients with a median MELD3.0 of 11 required hospitalization by 6-months. Routine assessment with LFI may improve risk stratification and guide interventions to reduce healthcare utilization. |
| Increasing incidence and prevalence of Microscopic Colitis in Sweden: A nationwide population-based cohort study.
In Sweden, incidence and prevalence of MC continued to rise through 2021. The steeper slope of MC incidence in relation to normal mucosa indicates either a true rise in disease occurrence or an ongoing diagnosis of prevalent cases related to an increased awareness of MC. |
| Interval positive fecal immunochemical test is associated with post-colonoscopy colorectal cancer in a screening program.
Patients with a positive interval FIT are at increased risk of PCCRC and should be offered repeat colonoscopy. |
| Long-term outcomes of endoscopic submucosal dissection for esophageal squamous high-grade dysplasia and early squamous cell carcinoma in the west: Absolute versus Outside Criteria.
ESD offers excellent procedural outcomes and provides definitive T-staging for oesophageal squamous HGD and ESCC in Western practice. In those meeting AC, the majority are cured and achieve excellent long-term OS. In the non-cured, mostly OC lesions in the elderly and comorbid, ESD provides durable local disease control and facilitates organ-preservation. Thus, ESD should be considered at the forefront of therapeutic consideration. |
| Polygenic Risk Score Predicts Prognosis in Non-obese MASLD but Not in Obese MASLD in Japan: A Multicenter Cohort Study.
In biopsy-proven MASLD, PRS-2 improves LRE prediction regardless of obesity and shows the strongest association with OS among non-obese patients; these OS associations were not reproduced in a predominantly mild-spectrum, non-biopsied cohort. |
| Reliability of Hepatic Steatosis Quantification by Controlled Attenuation Parameter in Steatotic Liver Disease.
The MDC of CAP is >57-69 dB/m (>18-25%) and substantially greater in a longitudinal setting and advanced disease. |
| Twenty-Year Trends in Liver Transplantation Among Hepatitis D Virus-Infected Patients in the U.S. and Europe.
Compared with HBV-monoinfected recipients, HBV/HDV recipients were transplanted younger with more advanced liver disease, underscoring the urgent need for HDV-targeted therapies. Despite their worse pre-transplant profile, HDV patients achieve comparable or superior post-transplant survival. |
| U.S. Experience with Terlipressin in Hepatorenal Syndrome: Response, Mortality, and Transplant Outcomes - Results from the HRS Harmony Consortium.
This U.S. multicenter study provides insights into real-world use of terlipressin for HRS-AKI. Terlipressin was frequently used in patients with ACLF grade 3. Adherence to FDA labeling criteria was associated with superior efficacy and safety. The significant association between Overall Response and reduced mortality underscores its potential as a clinically relevant endpoint for future studies. |
| Endoscopy |
| Generative chromoendoscopy for gastric neoplasms: A multicenter prospective study.
Generative chromoendoscopy was feasible during live endoscopic procedures. It improved visibility of pre-identified gastric neoplasms compared with WLI and achieved visibility comparable to real chromoendoscopy. |
| Long-term Local Recurrence and Survival after Colorectal Endoscopic Submucosal Dissection: A Prospective Multicenter Real-world Cohort Study.
Colorectal ESD has a very low long-term local recurrence rate in real-world clinical settings. No recurrence was observed in patients who underwent curative resection, while long-term surveillance is warranted after non-curative resection. |
| Outcomes of perforation after colorectal endoscopic submucosal dissection in a large prospective multicenter cohort.
CONCLUSIONS: ESD-related perforations are often manageable conservatively, with surgery being rare; however, delayed perforations remain challenging and often require surgery. Patients should be informed of both the benefits and risks. |
| Percutaneous transhepatic biliary drainage versus endoscopic ultrasound-guided biliary drainage with primary metal stenting for unresectable malignant distal biliary obstruction.
EUS-BD, particularly EU-CDS, might be preferred over PTBD in unresectable MDBO in terms of better clinical success and lower biliary re-intervention rate. |
| Gastroenterology |
| Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer.
We uncover TAK1 as a critical mediator in maintaining genomic integrity and highlights its potential as a therapeutic target to induce an inflamed TME that sensitizes PDAC to ICB. |
| Neutrophil-Driven Trogocytosis in PDAC Liver Metastases Restrains Immunosuppressive Macrophage Polarization and Limits Metastatic Progression.
This study provides in vivo evidence of neutrophil-macrophage crosstalk in PDAC liver metastases and highlights the functional consequences of neutrophil depletion. By integrating intravital calcium imaging with single-cell RNA sequencing, we uncover a previously unrecognized mechanism of neutrophil-driven immunomodulation, emphasizing the potential for therapeutic strategies targeting neutrophil-macrophage interactions in metastatic PDAC. |
| Randomized Sham Controlled Trial of Translumbosacral Neuromodulation Therapy for Fecal Incontinence.
TNT treatments with 2400 and 3600 magnetic pulses showed superior efficacy in improving fecal incontinence and bowel symptoms when compared to sham treatment and was safe and well tolerated. |
| Gastrointest Endosc |
| Endoscopic resection of low-grade dysplasia Barrett's esophagus: A multicenter retrospective study.
Endoscopic therapy with EMR or ESD appears effective and safe for selected patients with LGD in BE, with low recurrence rates. In addition to lesion eradication, it provides histological assessment, allowing detection of more advanced pathology in some cases. These findings suggest that resection may represent a valuable adjunct or alternative within current treatment strategies. |
| Optimizing Indications and Diagnostic Performance of Computed Tomography Angiography in Acute Gastrointestinal Bleeding: A Large Cohort Study.
Although CTA may be unsuitable as an initial diagnostic modality for acute GI bleeding, its selective use-guided by a clinical prediction model-can help identify patients most likely to benefit, thereby reducing inappropriate use and improving the diagnostic yield of CTA. |
| Performance of Magnetic Resonance Imaging in the Staging of Rectal Polyps Undergoing Endoscopic Resection: A US Academic Cancer Center Experience.
We demonstrate that MRI over-stages over 40% (18/44) of large rectal polyps. MRI staging should be interpreted cautiously when considering endoscopic resection for large rectal polyps. |
| Treatment of recurrent esophageal strictures with a paclitaxel coated balloon dilator: Initial U.S. Experience.
Treatment of esophageal strictures with DCB demonstrated decreased recurrence of significant stricture compared to historical needs, improved dysphagia symptoms compared to baseline and limited systemic exposure to paclitaxel. Prospective randomized studies are needed to confirm these results. |
| Gut |
| Landscape screening identifies the lactate-modifying enzyme AARS2 as a master regulator and therapeutic target in hepatocellular carcinoma.
AARS2 links lactate metabolism to HCC progression via lactylation. Kukoamine A nanotherapy targeting this axis shows synergistic efficacy with immunotherapy, advancing the prospects of precision oncology. |
| Hepatology |
| Diabetes, male sex, low levels of HBsAg, HDV RNA and ALT predict spontaneous HDV suppression in chronic hepatitis D.
Diabetes, male sex, lower baseline HBsAg, HDV RNA and ALT independently predicted HDV spontaneous suppression. These factors may inform treatment decisions in this era of emerging anti-HDV therapies. |
| Exploring the interaction between metabolic dysfunction and alcohol-associated hepatitis: A global study.
Among patients with severe AH, metabolic dysfunction was not associated with increased mortality. Although a higher BMI was associated with slightly lower mortality in AH, this may reflect better nutritional status rather than a true protective effect. |
| Non-contrast abbreviated MRI demonstrates superior diagnostic accuracy compared to ultrasound for hepatocellular carcinoma detection: Interim results from a prospective surveillance trial.
A rapid, non-contrast AMRI protocol shows superior per-patient sensitivity compared to US for HCC detection in cirrhotic patients under surveillance. While these diagnostic findings are encouraging, prospective trials evaluating patient-level outcomes are essential before definitive guideline recommendations can be made. |
| Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study.
BSA-adjusted bevacizumab dosing was associated with improved efficacy without increased toxicity in patients with unresectable HCC treated with Atezo/Bev. |
| Palmitoylation-mediated exosomal trafficking of nuclear protein NAT10 potentiates liver fibrosis in MASH.
This study links aberrant nuclear protein localization to subsequent exosome-mediated fibrogenic signaling in MASH and demonstrates that targeting this pathway, either by disrupting palmitoylation-dependent mislocalization or by hepatocyte-specific Nat10 inhibition, ameliorates liver fibrosis with concurrent metabolic benefit. |
| J Hepatol |
| A Multi-Analyte cfDNA-based Blood Test for Early Detection of Hepatocellular Carcinoma.
The HelioLiver Dx test identified more HCC lesions overall and more small lesions compared to other testing modalities. An accurate and convenient blood-based test may improve HCC detection through earlier detection and reduced patient barriers to testing. identifier NCT03694600 IMPACT AND IMPLICATIONS There is a significant, unmet clinical need for more sensitive and accessible methods for the early detection of hepatocellular carcinoma (HCC) in high-risk patient populations. The current study is the first blinded, multicenter, prospective study to evaluate the performance of a multianalyte blood test compared to abdominal ultrasound for the detection of HCC among patients with cirrhosis. The multianalyte HelioLiver Dx test met prespecified co-primary endpoints for superior sensitivity and non-inferior specificity compared to ultrasound for detection of HCC lesions. The availability of a more accessible, convenient and sensitive blood test to aid in the detection of HCC may improve utilization and consequently clinical outcomes for high-risk patients via reduction of care barriers and improved early HCC detection. |
| Arachidonoyl-taurine is elevated in human MASLD and protects against hepatic steatosis and inflammation in preclinical models.
ARA-T is an endogenous metabolite that increases with human hepatic steatosis and reduces murine hepatic lipid content independent of weight loss, demonstrating its direct action and potential to reverse the progression of liver disease. Impact and implications Metabolic dysfunction-associated steatotic liver disease (MASLD) is among the most prevalent forms of liver disease worldwide and is likely to affect more than half of the global population in the next decade, with limited treatment options available. Here, we identified an endogenous, uncharacterized omega-6 fatty acid metabolite, arachidonoyl-taurine (ARA-T), capable of mitigating steatotic liver disease and reducing hepatic inflammation by increasing hepatic fatty acid oxidation. This study positions ARA-T as an endogenous molecule with hepatoprotective effects and provides a potential target that lays the foundation for future treatment of MASLD. |
| CD34<sup>+</sup> cell-Derived Endothelial Cells Orchestrate Vascular and Immune Remodeling in the Transplanted Liver.
We identified a population of recipient CD34 + cell-derived ECs that exacerbated acute rejection by activating T cells via the CXCL12-CXCR4 axis, and offered a platelet-based delivery strategy that precisely targeted ECs' CXCL12 and effectively prevented acute cellular rejection. Impact and implications We collected and integrated single-cell transcriptomic data from the liver allografts in both human and mice, delineating dual cellular origins and functional atlas of endothelial cells. We constructed lineage-tracing mice to track CD34 + cell fate in allogeneic mouse orthotopic liver transplantation model, demonstrating the involvement of recipient CD34-lineage endothelial cells in liver allograft angiogenesis. CD34-lineage endothelial cells recruit T cells via CXCL12-CXCR4 axis and activate them through co-stimulatory molecules. Using a platelet-based biologically delivery strategy to neutralize CXCL12 in CD34-lineage endothelial cells alleviated T cell-mediated rejection. This study provides an endothelial cell-based perspective and protocol for a novel immunosuppressive regimen after liver transplantation. |
| Rifaximin ameliorates cirrhotic portal hypertension through suppression of microbiome-derived deoxycholic acid.
Microbiome-derived DCA exacerbates PH by enhancing TPH1-dependent 5-HT biosynthesis, which activates PVSMC contraction via HTR1A-GIRK3 signaling. Rifaximin alleviates cirrhotic PH by reducing DCA levels, highlighting a potential therapeutic strategy for clinical PH management. Impact and implications Portal hypertension is a key driver of cirrhosis-related complications, yet current therapies exhibit suboptimal efficacy. Herein, we elucidate the role of the gut microbial metabolite DCA in the pathophysiology of cirrhotic portal hypertension through the TPH1-5-HT/HTR1A-GIRK3 axis and provide preclinical evidence that rifaximin ameliorates cirrhotic portal hypertension by reducing DCA. These insights may open a new avenue for the clinical management of cirrhotic portal hypertension. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
| Editorial: Bile Acids Under Bulevirtide: A Pharmacodynamic Signature, Not a Prognostic Biomarker. |
| Editorial: Inflammatory Bowel Disease Care Pathways-Improving Quality, but Not at Increased Cost. |
| Editorial: Refining the Natural History of MASLD by Imaging-Based Markers: The GOLDMINE Study. |
| Gastroenterology |
| Codex in limbo? Using the Interleukin-2 (IL-2) test to lower the bar for gluten in a gluten-free diet for celiac disease. |
| Molecular Eyes on the Bile Duct: Next-Generation Sequencing Earns Its Place in Biliary Stricture Evaluation. |
| J Hepatol |
| A call for sharing individual patient data from trials in hepatology.
To succeed, IPD must be shared with other researchers. Here we present the history of IPD sharing, the past and current proportions of hepatology trials stating their willingness to share IPD, and our own experience with reuse of IPD data from hepatology trials. |
| The role of liver sinusoidal endothelial cells in liver diseases: Key players in health and pathology.
Despite innovative tools supporting the dissection of LSEC heterogeneity, our understanding of LSEC pathobiology remains limited and characterised by important gaps. This review highlights recent discoveries and examines possible innovative therapeutic strategies targeting LSECs in liver disease. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| Correction to: Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis. |
| Primer: Understanding Medicare for Advanced Therapies for Inflammatory Bowel Disease. |
| Clin Gastroenterol Hepatol |
| Direct-to-Consumer Pharmacies and "Direct" Drug Channels: Practice Implications for Gastroenterology and Hepatology. |
| Long-term loss of response to proton pump inhibitors is uncommon in adult eosinophilic esophagitis. |
| Endoscopy |
| A novel flexible endoscopic C-shaped suturing device for colonic wound closure in a porcine model. |
| An unexpected appendiceal orifice mass. |
| Black hole in WONderland: endoscopic management of walled-off necrosis complicated by giant colonic fistula. |
| Direct pancreatic duct orifice incision for complete obstruction after intraductal radiofrequency. |
| Diverticular per oral endoscopic septotomy with selective crurotomy as salvage therapy for severe esophagogastric junction outflow obstruction after endoscopic and surgical therapy. |
| Effective robotic arm-assisted traction for endoscopic submucosal dissection treating ulcerative colitis-associated colonic neoplasia. |
| Endoscopic hand suturing with muscle anchoring for complete defect closure after endoscopic submucosal dissection. |
| Endoscopic removal using perioral cholangioscopy for biliary migration of vascular coil placed to treat biliary tract bleeding caused by ruptured right hepatic artery aneurysm. |
| Endoscopic submucosal dissection of polypoid solitary rectal ulcer. |
| Endoscopic submucosal tunneling resection via a transantral approach for duodenal bulb gastrointestinal stromal tumor. |
| Endoscopic transcolonic appendiceal detachment - a novel management for appendicitis. |
| Endoscopic ultrasonographically guided magnetic side-to-side entero-enterostomy. |
| Endoscopic ultrasound diagnosis and management of mass-forming chronic pancreatitis with situs inversus. |
| Endoscopic ultrasound-guided ethanol ablation for mediastinal parathyroid adenoma complicated by recurrent laryngeal nerve injury: a case report. |
| Endoscopic ultrasound‑guided stricturotomy for complete anastomotic occlusion following Hartmann's reversal. |
| Innovative employment of fistuloscope to cure complex ultra-low ileorectal anastomotic leakage. |
| Intraprocedural bleeding in endoscopic submucosal dissection and third-space endoscopy: is prevention the best treatment? |
| Next-generation reopenable-clip over-the-line method for gastric defects after endoscopic submucosal dissection at an anastomotic site. |
| Pyloric balloon occlusion-assisted endoscopic ultrasound-guided gastroenterostomy for an impassable duodenal stricture. |
| Retrograde-antegrade rendezvous recanalization for complete cervical esophageal obstruction after chemoradiotherapy: a novel organ-preserving approach. |
| Rewiring facilitation during inside plastic stent exchange in malignant hilar biliary obstruction. |
| Short-type hydrophilic guidewire for reintervention after metal stents placement in malignant hilar biliary obstruction. |
| Gastroenterology |
| A 64-year-old patient with T1b esophageal adenocarcinoma: what treatment options do we have? |
| A Randomized Trial of Colonoscopy versus Fecal Immunochemical Testing versus Usual Care in the Detection of Colorectal Cancer. |
| An unusual biliary manifestation in a patient with familial adenomatous polyposis: What is your diagnosis? |
| EFFECTIVENESS OF RISANKIZUMAB AFTER USTEKINUMAB FAILURE IN CROHN'S DISEASE: A MULTICENTER RETROSPECTIVE COHORT STUDY. |
| From Gut Sensing to Feeding Suppression: Tuft-Enterochromaffin Cell Crosstalk Reveals a New Frontier in Gut-Brain Communication. |
| GLP-1 Receptor Agonists and Upper Endoscopy - Guidance for Periprocedural Management. |
| Gut microbiome interactions can predict health and disease states. |
| Initial vancomycin taper may reduce early recurrence of Clostridioides difficile infection. |
| Is the Gluten-Free Diet Enough? Targeting Fiber Metabolism in Celiac Disease. |
| Learning from CAR T-Cell Therapy in Pediatric Autoimmunity: Potential Applications for Gastroenterology. |
| Multiple Pancreatic Masses in a Young Woman: What Are We Really Treating? |
| Gastrointest Endosc |
| Top tips for traction during endoscopic submucosal dissection. |
| Ultra-acute-onset arytenoid congestion during esophagogastroduodenoscopy. |
| Gut |
| CD16<sup>+</sup> γδ T cells and antibody-dependent cellular cytotoxicity: a new axis of immune control in hepatitis B virus infection? |
| Endoluminal device induces insulin sensitivity and greater weight control than semaglutide in pigs. |
| Metabolic mechanisms of duodeno-ileal diversion: early bile acid and incretin signalling predict glycaemic outcomes. |
| Seeing the unseen: AI radiomics unmasking occult pancreatic cancer? |
| Tumour-autonomous IL-6 signalling creates a metabolic vulnerability in intrahepatic cholangiocarcinoma. |
| Hepatology |
| Buying time: Therapeutic plasma exchange as a bridge to transplant in acute-on-chronic liver failure. |
| Consistent efficacy of efruxifermin across PNPLA3 genotypes in phase 2b trials in MASH. |
| J Hepatol |
| Extracorporeal xenogeneic liver support: Defining the first clinical niche. |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Editorial: Refining the Natural History of MASLD by Imaging-Based Markers: The GOLDMINE Study. Authors' Reply. |
| Editorial: The Milan Score as Supportive Evidence of Gastro-Oesophageal Reflux Disease. Authors' Reply. |
| Letter: Disease Stage and Absolute Risk in Evaluating the Branched-Chain Amino Acid to Tyrosine Ratio in Cirrhosis. |
| Letter: Does Serum HBV RNA Add Incremental Value for Hepatocellular Carcinoma Risk Stratification Beyond Established Predictors? |
| Letter: Does Serum HBV RNA Add Incremental Value for Hepatocellular Carcinoma Risk Stratification Beyond Established Predictors? Authors' Reply. |
| Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease. Authors' Reply. |
| Letter: Geographic Transportability of Shingles Risk With Advanced IBD Therapies. |
| Letter: Interpreting Faecal SCFA Enrichment in IBS-D-Metabolic Signal or Transit-Related Marker? |
| Letter: More Precise Stratification Is Needed Within Chronic Hepatitis B Virus Low-Level Viraemia. |
| Letter: Reassessing Liver Biopsy Deferral in Antinuclear Antibody-Positive Patients: The Clinical Necessity of Objective Fibrosis Staging. |
| Letter: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants. |
| Letter: Therapeutic Targeting of PPARs in PBC-Additional Considerations. |
| Letter: Unmasking the Risks-The Need for Robust Data on Baclofen in Cirrhotic Patients. Authors' Reply. |
| Gastroenterology |
| Beyond Pancreatitis: What Primary EUS-CDS Means for Surgery and Patient-Centered Outcomes. |
| Comment on "Mutational Landscape of Colorectal Tumors From Individuals With Unexplained Adenomatous or Serrated Colorectal Polyposis". |
| EUS-CDS in Malignant Distal Biliary Obstruction: Moving Beyond Technical Success Toward Personalized Patient Selection. |
| EUS-Guided Choledochoduodenostomy Versus ERCP for the Primary Prevention of Pancreatitis: An Unfair Comparison. |
| EUS-choledochoduodenostomy with LAMS: Here to Stay, but All That Glitters Is Not Gold. |
| EUS-guided choledochoduodenostomy instead of ERCP as first-line biliary drainage: what are the remaining barriers to wider adoption? |
| EUS-guided choledochoduodenostomy or ERCP for distal malignant obstruction: the debate continues. |
| Methodological considerations in the mutational landscape of unexplained polyposis. |
| Misinterpretation of SBS89 Undermines Claims on BRAF-Mutated Polyps. |
| Not all gold, yet still a valuable option: EUS-guided choledochoduodenostomy as first-line drainage in dilated bile ducts. |
| Pancreatic Duct Stenting and Interpretation of the ERCP Comparator Arm in Malignant Distal Biliary Obstruction. |
| Gut |
| Maternal influenza infection during pregnancy and subsequent risk of inflammatory bowel diseases in offspring: a nationwide birth cohort study in South Korea. |
| J Hepatol |
| Extended Longitudinal Validation of Serum Procalcitonin as a Biomarker for Fibrolamellar Hepatocellular Carcinoma. |
| Rejection and perioperative management in liver transplantation following immune checkpoint inhibitor-based downstaging for hepatocellular carcinoma. |